[Factors of response to treatment with interferon-alpha in patients with chronic hepatitis C. Therapeutic perspectives].
Marcellin
P
P
INSERM U24, Hôpital Beaujon, Clichy.
Pouteau
M
M
Martinot
M
M
Boyer
N
N
Castelnau
C
C
Benhamou
J P
JP
Erlinger
S
S
D000367:Age Factors; D000998:Antiviral Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000628:therapy* / Q000821:virology; D006521:Hepatitis, Chronic / Q000628:therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects; D008297:Male; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use; D012737:Sex Factors
D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin
Facteurs de réponse au traitement par l'interféron alpha chez les malades atteints d'hépatite chronique C. Perspectives thérapeutiques.